CRISPR Therapeutics fell 20.8% from $50.73 to $40.19, behind the S&P 500's +10.2%. Its worst day was Apr 24 (−11.6%), and its low came Nov 17 at $40.15.
Story events cover the past 12 months · Times ET
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
CRISPR Therapeutics shares rose 11.1%, while the S&P 500 rose 0.5%.
+11.1% · S&P 500 +0.5%
EPS of $-1.37 missed the $-1.20 estimate on $864,000.00 revenue (est. $3.9M).
+8.5% · S&P 500 +0.1%
CRISPR Therapeutics shares rose 11.8%, while the S&P 500 fell 0.6%.
+11.8% · S&P 500 −0.6%
- CRISPR Therapeutics AG (NASDAQ:CRSP) (the "Company") today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its convertible senior no…
−10.2%, on 9M shares, the year's heaviest volume · S&P 500 −0.2%
CRISPR Therapeutics shares fell 11.6%, while the S&P 500 rose 0.8%.
−11.6%, the year's worst day · S&P 500 +0.8%
EPS of $-1.28 missed the $-1.22 estimate on $1.5M revenue (est. $5.1M).
−2.2% · S&P 500 +0.8%
CRISPR Therapeutics closed at its highest level of the year, 22.0% above where the year started.
+3.0% · S&P 500 +0.9%
EPS of $-0.94 beat the $-1.18 estimate on $10.2M revenue (est. $7.1M).
+7.1% · S&P 500 +1.8%
CRISPR Therapeutics shares rose 12.9%, while the S&P 500 rose 0.2%.
+12.9%, the year's best day · S&P 500 +0.2%
EPS of $-1.15 missed the $-1.06 estimate on $12.7M revenue (est. $15.2M).
−2.8% · S&P 500 −0.5%
Where it ended: a close of $40.19 on Nov 18, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $-1.20, revenue est. $11.7M).
Nothing in the past 12 months.
All CRSP dividend history